SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-23-087945
Filing Date
2023-11-16
Accepted
2023-11-16 16:51:23
Documents
14
Period of Report
2023-11-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea188598-8k_virpaxpharma.htm   iXBRL 8-K 26556
2 PRESS RELEASE ISSUED BY VIRPAX PHARMACEUTICALS, INC. DATED NOVEMBER 15, 2023 ea188598ex99-1_virpaxpharma.htm EX-99.1 63096
3 GRAPHIC ex99-1_001.jpg GRAPHIC 7398
  Complete submission text file 0001213900-23-087945.txt   285860

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE vrpx-20231115.xsd EX-101.SCH 3027
5 XBRL LABEL FILE vrpx-20231115_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE vrpx-20231115_pre.xml EX-101.PRE 22367
8 EXTRACTED XBRL INSTANCE DOCUMENT ea188598-8k_virpaxpharma_htm.xml XML 3420
Mailing Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312
Business Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-4597
Virpax Pharmaceuticals, Inc. (Filer) CIK: 0001708331 (see all company filings)

IRS No.: 821510982 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40064 | Film No.: 231415273
SIC: 2834 Pharmaceutical Preparations